PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie …
All news - Pipelinereview
3 days ago · BRUSSELS, Belgium and CAMBRIDGE, MA, USA I November 19, 2024 I UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed results …
Vaccines - Pipelinereview
Oct 7, 2024 · BRISBANE, Australia & CAMBRIDGE, MA, USA I October 28, 2024 I Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch …
Pimicotinib Significantly Improved Outcomes for Patients with ...
Nov 12, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & …
GSK announces positive phase III results from ANCHOR trials for ...
Oct 14, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & …
Lilly's mirikizumab is first and only IL23p19 antagonist to report …
Oct 28, 2024 · Antibodies. Lilly’s mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn’s disease
Otsuka Provides Update on Sibeprenlimab, an Investigational …
3 days ago · PRINCETON, NJ, USA & TOKYO, Japan I November 19, 2024 I Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical, …
Three Phase 3 Trials of Datopotamab Deruxtecan-Based …
Oct 31, 2024 · TOKYO, Japan & BASKING RIDGE, NJ, USA I October 30, 2024 I The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy …
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO …
Sep 10, 2024 · Full data from the primary analysis of the positive, single-arm Phase 2 PICCOLO trial, evaluating mirvetuximab soravtansine (ELAHERE®), for high folate receptor-alpha (FRα) …
TREMFYA® (guselkumab) demonstrates impressive results across …
Oct 10, 2024 · TREMFYA ® is now U.S. FDA-approved for ulcerative colitis and under review for Crohn’s disease. TREMFYA ® is the only IL-23 inhibitor to demonstrate superiority to …